banner-trabalhos-cientificos-1360x237px.png

PUBLICAÇÕES CIENTÍFICAS

Publicações científicas resultantes de projetos de pesquisa da Equipe IBPClin. 

FRACTURE-RISK-AND-ZOLEDRONIC.jpg
FRACTURE RISK AND ZOLEDRONIC ACID THERAPY IN MEN WITH OSTEOPOROSIS
THE NEW ENGLAND JOURNAL OF MEDICINE • NOV. 2012
EFFECTS-OF-TERIPARATIDE-COMPARED-WITH-RISEDRONATE---JBMR.jpg
EFFECTS OF TERIPARATIDE COMPARED WITH RISEDRONATE ON THE RISK OF FRACTURES IN SUBGROUPS OF POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS: THE VERO TRIAL.
JOURNAL OF BONE AND MINERAL RESEARCH, VOL. 33 • 2018
LANCET-EFFECTS-OF-TERIPARATIDE-AND-RISEDRONATE.jpg
EFFECTS OF TERIPARATIDE AND RISEDRONATE ON NEW FRACTURES IN POST-MENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS (VERO): A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED CONTROLLED TRIAL
LANCET; 391: 230–40, PUBLISHED ONLINE • JAN. 2018
IOF-THE-EFFECT-OF-TERIPARATIDE-COMPARED-WITH-RISEDRONATE-ON-REDUCTION-OF-BACK-PAIN-IN-POST
THE EFFECT OF TERIPARATIDE COMPARED WITH RISEDRONATE ON REDUCTION OF BACK PAIN IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROTIC VERTEBRAL FRACTURES
INTERNATIONAL OSTEOPOROSIS FOUNDATION AND NATIONAL OSTEOPOROSIS FOUNDATION 2011 • 2011
BONE-MINERAL-DENSITY.jpg
BONE MINERAL DENSITY RESPONSE RATES ARE GREATER IN PATIENTS TREATED WITH ABALOPARATIDE COMPARED WITH THOSE TREATED WITH PLACEBO OR TERIPARATIDE: RESULTS FROM THE ACTIVE PHASE 3 TRIAL
ELSEVIER BONE 120: 137 - 140 • OUT. 2018
A-IMPORTANCIA-DA-PESQUISA-CLINICA-PARA-O-BRASIL.jpg
A IMPORTÂNCIA DA PESQUISA CLÍNICA PARA O BRASIL
INTERFARMA - JULHO 2019
ART-TESE-VIT-D.jpg
DETERMINAR O VALOR DE 25OH D EM UMA POPULAÇÃO DE MULHERES PÓS-MENOPÁUSICAS COM MAIS DE 60 ANOS COM OSTEOPENIA E OSTEOPOROSE E A CORRELAÇÃO COM PARÂMETROS DO METABOLISMO ÓSSEO E FRATURAS VERTEBRAIS.
FUNDAÇÃO OSVALDO CRUZ – IFF • OUTUBRO 2006
IS-IT-ETHICAL-TO-USE-PLACEBOS-IN-OSTEOPOROSIS-TRIALS.jpg
IS IT ETHICAL TO USE PLACEBOS IN OSTEOPOROSIS TRIALS?
JOURNAL OF CLINICAL DENSITOMETRY, VOL. 9, NO. 3, 274E280 • 2006
POSTMENOPAUSAL-OSTEOPOROSIS.jpg
POSTMENOPAUSAL OSTEOPOROSIS
THE NEW ENGLAND JORNAL OF MEDICINE, 353:595-603 • 2005
PERFIL-DE-SUJEITOS-DE-PESQUISA-CLÍNICA-EM-UM-CENTRO-AMBULATORIAL-INDEPENDENTE.jpg
PERFIL DE SUJEITOS DE PESQUISA CLÍNICA EM UM CENTRO AMBULATORIAL INDEPENDENTE
CIÊNCIA & SAÚDE COLETIVA, 13(3) • 2008
WWV51932.jpg
SAFETY AND TOLERABILITY OF BAZEDOXIFENE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM A 3-YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED CLINICAL TRIAL
ASBMR MEETING • 2007
ASSOCIATION-OF-BACK-PAIN-WITH-HYPOVITAMINOSIS-D-IN-POSTMENOPAUSAL-WOMEN-WITH-LOW-BONE-MASS
ASSOCIATION OF BACK PAIN WITH HYPOVITAMINOSIS D IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS
BMC MUSCULOSKELETAL DISORDERS, 14:184 • 2013
denosumab.jpg
DENOSUMAB ADMINISTRATION IS NOT ASSOCIATED WITH FRACTURE HEALING COMPLICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM TRIAL
ASBMR 32ND ANNUAL MEETING, TORONTO, ONTARIO • OCTOBER 15–19, 2010
CONCENTRACAO.jpg
CONCENTRAÇÃO PLASMÁTICA DE 25 HIDROXIVITAMINA D EM MULHERES NA PÓS-MENOPAUSA COM BAIXA DENSIDADE MINERAL ÓSSEA
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA • DEZEMBRO 2009
FREEDOM-ADAMI-2010.jpg
EFFECT OF DENOSUMAB ON FRACTURE HEALING IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM TRIAL
EUROPEAN SYMPOSIUM ON CALCIFIED TISSUES 37TH CONGRESS, GLASGOW, UK • JUNE 26 –30, 2010
GLUCOCORTICOID-INDUCED-OSTEOPOROSIS.jpg
GLUCOCORTICOID-INDUCED OSTEOPOROSIS
ARQUIVOS BRASILEIROS ENDOCRINOLOGIA E METABOLOGIA, VOL 50 Nº 4 • AGOSTO 2006
EFFECT-OF-DENOSUMAB-VS-ALENDRONATE.jpg
EFFECT OF DENOSUMAB VS ALENDRONATE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY CHANGES AT 12 MONTHS BASED ON BASELINE BONE TURNOVER LEVEL
THE JOURNAL OF RHEUMATOLOGY, 36:11 • 2009
COMPARISON-OF-THE-EFFECT-OF-DENOSUMAB-AND-ALENDRONATE-ON-BMD-AND-BIOCHEMICAL.jpg
COMPARISON OF THE EFFECT OF DENOSUMAB AND ALENDRONATE ON BMD AND BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS: A RANDOMIZED, BLINDED, PHASE 3 TRIAL
JOURNAL OF BONE AND MINERAL RESEARCH, VOLUME 24, NUMBER 1 • 2009
PERCENTAGE-OF-WOMEN-ACHIEVING-NON-OSTEOPOROTIC.jpg
PERCENTAGE OF WOMEN ACHIEVING NON-OSTEOPOROTIC BMD T-SCORES AT THE SPINE AND HIP OVER 8 YEARS OF DENOSUMAB TREATMENT
JOURNAL OF BONE AND MINERAL RESEARCH, VOLUME 24, NUMBER 1 • 2009
RELATIONSHIP-BETWEEN-BONE-MINERAL-DENSITY-T‐SCORE.jpg
RELATIONSHIP BETWEEN BONE MINERAL DENSITY T‐SCORE AND NONVERTEBRAL FRACTURE RISK OVER 10 YEARS OF DENOSUMAB TREATMENT
JOURNAL OF BONE AND MINERAL RESEARCH, VOL. 34, NO. 6, P. 1033–1040 • 2019
Osteoporosis-int-2011.jpg
FREEDOM TRIAL: DENOSUMAB IS NOT ASSOCIATED WITH FRACTURE HEALING COMPLICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
OSTEOPOROSIS INT 22 (SUPPL 1):S119–S408 • 2011
Osteoporosis-int-2015.jpg
PERCENTAGE OF WOMEN ACHIEVING NON-OSTEOPOROTIC BMD T-SCORES AT THE LUMBAR SPINE (LS) AND TOTAL HIP (TH) DURING UP TO 8 YEARS OF DENOSUMAB (DMAB) TREATMENT
OSTEOPOROSIS INT  26 (SUPPL 1):S71–S380 • 2015
Osteoporosis-int-2016.jpg
RELATIONSHIP BETWEEN TOTAL HIP BMD T-SCORE AND INCIDENCE OF NONVERTEBRAL FRACTURE WITH UP TO 10 YEARS OF DENOSUMAB (DMAB) TREATMENT
OSTEOPOROSIS INT 27 (SUPPL 1):S39–S62 • 2016